MYClo&GZMKhi (N=10)	Other (N=12)	MYChi&GZMKlo (N=11)	P-value
Age
Mean (SD)	47.4 (8.58)	43.1 (9.15)	42.1 (8.49)	0.437
Median [Min, Max]	49.5 [32.0, 61.0]	40.0 [32.0, 64.0]	39.0 [32.0, 58.0]
Gender
Female	2 (20.0%)	4 (33.3%)	1 (9.1%)	0.362
Male	8 (80.0%)	8 (66.7%)	10 (90.9%)
ECOG
0	5 (50.0%)	4 (33.3%)	5 (45.5%)	0.711
1	5 (50.0%)	8 (66.7%)	6 (54.5%)
Number.of.metastatic.site
>=2	9 (90.0%)	12 (100%)	11 (100%)	0.305
0-1	1 (10.0%)	0 (0%)	0 (0%)
Previous_immunotherapy
N	6 (60.0%)	3 (25.0%)	6 (54.5%)	0.197
Y	4 (40.0%)	9 (75.0%)	5 (45.5%)
Lines.of.therapy
>=2	8 (80.0%)	10 (83.3%)	11 (100%)	0.311
0-1	2 (20.0%)	2 (16.7%)	0 (0%)
dNLR
<=3	8 (80.0%)	10 (83.3%)	8 (72.7%)	0.819
>3	2 (20.0%)	2 (16.7%)	3 (27.3%)
LDH
<=ULN	5 (50.0%)	8 (66.7%)	2 (18.2%)	0.062
>ULN	5 (50.0%)	4 (33.3%)	9 (81.8%)
Albumin
<3.5 g/dL	0 (0%)	0 (0%)	1 (9.1%)	0.357
>=3.5 g/dL	10 (100%)	12 (100%)	10 (90.9%)
Liver.metastasis
no	6 (60.0%)	7 (58.3%)	2 (18.2%)	0.0839
yes	4 (40.0%)	5 (41.7%)	9 (81.8%)
Previous_radiation_therapy
N	3 (30.0%)	1 (8.3%)	1 (9.1%)	0.292
Y	7 (70.0%)	11 (91.7%)	10 (90.9%)
Smoking_history
No	6 (60.0%)	10 (83.3%)	10 (90.9%)	0.199
Yes	4 (40.0%)	2 (16.7%)	1 (9.1%)
BMI
Mean (SD)	22.8 (3.05)	21.7 (2.27)	21.9 (3.30)	0.404
Median [Min, Max]	22.2 [19.4, 29.3]	21.9 [18.1, 25.4]	21.9 [17.8, 29.0]
ICI_response
PR	6 (60.0%)	2 (16.7%)	0 (0%)	0.00206
SD	3 (30.0%)	3 (25.0%)	0 (0%)
PD	1 (10.0%)	7 (58.3%)	9 (81.8%)
Missing	0 (0%)	0 (0%)	2 (18.2%)